CLINICAL TRIALS PROFILE FOR HEMATOPORPHYRIN

Clinical Trials for Hematoporphyrin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00004430 ↗	Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	Completed	Eastern Virginia Medical School	N/A	OBJECTIVES: I. Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser photodynamic therapy (PDT) in patients with corneal neovascularization. II. Document the histopathologic mechanism of action in selected patients undergoing penetrating keratoplasty following PDT therapy for corneal neovascularization. III. Facilitate FDA product approval of DHP as a photosensitizing agent for laser treatment in these patients. IV. Explore the use of this photosensitizer for ocular and cutaneous basal cell and squamous cell carcinoma.
NCT00004430 ↗	Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	Completed	Medical College of Hampton Roads	N/A	OBJECTIVES: I. Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser photodynamic therapy (PDT) in patients with corneal neovascularization. II. Document the histopathologic mechanism of action in selected patients undergoing penetrating keratoplasty following PDT therapy for corneal neovascularization. III. Facilitate FDA product approval of DHP as a photosensitizing agent for laser treatment in these patients. IV. Explore the use of this photosensitizer for ocular and cutaneous basal cell and squamous cell carcinoma.
NCT00014066 ↗	Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer	Completed	Roswell Park Cancer Institute	Phase 1	RATIONALE: Photodynamic therapy uses light and drugs that make cnacer cells more sensitive to light to kill tumor cells. Brachytherapy uses radiation to damage tumor cells. Photodynamic therapy combined with brachytherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy plus brachytherapy in treating patients with recurrent lung cancer that is blocking the lung passages.
NCT00118222 ↗	High Light and Low Light Dose PDT in Glioma	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized clinical trial is studying two different light doses of photodynamic therapy using porfimer sodium to compare how well they work in treating patients who are undergoing surgery for recurrent malignant astrocytoma.
NCT00118222 ↗	High Light and Low Light Dose PDT in Glioma	Completed	Case Comprehensive Cancer Center	Phase 3	RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized clinical trial is studying two different light doses of photodynamic therapy using porfimer sodium to compare how well they work in treating patients who are undergoing surgery for recurrent malignant astrocytoma.
NCT02068157 ↗	Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer	Terminated	National Cancer Institute (NCI)	Phase 2	This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back. Interstitial photodynamic therapy uses a combination of laser light and a light-sensitive drug called porfimer sodium to destroy tumors. During treatment a laser light is used to activate the drug. Interstitial photodynamic therapy may be an effective treatment for head and neck cancer.
NCT02068157 ↗	Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer	Terminated	Roswell Park Cancer Institute	Phase 2	This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back. Interstitial photodynamic therapy uses a combination of laser light and a light-sensitive drug called porfimer sodium to destroy tumors. During treatment a laser light is used to activate the drug. Interstitial photodynamic therapy may be an effective treatment for head and neck cancer.

Clinical Trial Conditions for Hematoporphyrin

Condition Name

Condition Name
Intervention	Trials
Pleural Disorder	2
Corneal Neovascularization	1
Recurrent Oropharyngeal Squamous Cell Carcinoma	1
Lung Cancer	1

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	3
Lung Neoplasms	3
Mesothelioma	2
Cholangiocarcinoma	2

Clinical Trial Locations for Hematoporphyrin

Trials by Country

Trials by Country
Location	Trials
China	11
United States	6

Trials by US State

Trials by US State
Location	Trials
New York	4
Ohio	1
Virginia	1

Clinical Trial Progress for Hematoporphyrin

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Completed	3
Terminated	1

Clinical Trial Sponsors for Hematoporphyrin

Sponsor Name

Sponsor Name
Sponsor	Trials
Roswell Park Cancer Institute	4
National Cancer Institute (NCI)	3
Case Comprehensive Cancer Center	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	10
NIH	3